Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Inflammation stimulates immunity but can create immune privilege in some settings. Here, we show that cutaneous Leishmania major infection stimulated expression of the immune regulatory enzyme indoleamine 2,3 dioxygenase (IDO) in local lymph nodes. Induced IDO attenuated the T cell stimulatory functions of dendritic cells and suppressed local T cell responses to exogenous and nominal parasite antigens. IDO ablation reduced local inflammation and parasite burdens, as did pharmacologic inhibition of IDO in mice with established infections. IDO ablation also enhanced local expression of proinflammatory cytokines and induced some CD4(+) T cells to express interleukin (IL) 17. These findings showed that IDO induced by L. major infection attenuated innate and adaptive immune responses. Thus, IDO acts as a molecular switch regulating host responses, and IDO inhibitor drugs are a potential new approach to enhance host immunity to established leishmania infections.

[1]  B. Baban,et al.  B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase , 2010, Proceedings of the National Academy of Sciences.

[2]  C. Hunter,et al.  IL-27 Regulates IL-10 and IL-17 from CD4+ Cells in Nonhealing Leishmania major Infection1 , 2009, The Journal of Immunology.

[3]  B. Baban,et al.  IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells1 , 2009, The Journal of Immunology.

[4]  B. Baban,et al.  Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. , 2009, Immunotherapy.

[5]  H. Bang,et al.  Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type Immunity1 , 2009, The Journal of Immunology.

[6]  D. Munn,et al.  Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. , 2009, Blood.

[7]  Sarman Singh,et al.  Immunobiology of leishmaniasis. , 2009, Indian journal of experimental biology.

[8]  Y. Belkaid,et al.  Regulatory T cells in the control of host-microorganism interactions (*). , 2009, Annual review of immunology.

[9]  Y. Belkaid,et al.  Arming Treg cells at the inflammatory site. , 2009, Immunity.

[10]  Y. Iwakura,et al.  IL-17 Promotes Progression of Cutaneous Leishmaniasis in Susceptible Mice1 , 2009, The Journal of Immunology.

[11]  F. Tacchini-Cottier,et al.  Intralesional Regulatory T-Cell Suppressive Function during Human Acute and Chronic Cutaneous Leishmaniasis Due to Leishmania guyanensis , 2009, Infection and Immunity.

[12]  Y. Belkaid,et al.  Regulatory T Cells in the Control of Host-Microorganism , 2009 .

[13]  P. Puccetti,et al.  Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. , 2009, Microbes and infection.

[14]  G. Prendergast,et al.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.

[15]  C. Bogdan,et al.  The innate immune response against Leishmania parasites. , 2008, Immunobiology.

[16]  D. Munn,et al.  Creating immune privilege: active local suppression that benefits friends, but protects foes , 2008, Nature Reviews Immunology.

[17]  B. Baban,et al.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. , 2007, The Journal of clinical investigation.

[18]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[19]  Trinad Chakraborty,et al.  Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. , 2006, The Journal of clinical investigation.

[20]  Y. Belkaid,et al.  CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence , 2006, The Journal of experimental medicine.

[21]  N. Peters,et al.  Immune privilege in sites of chronic infection: Leishmania and regulatory T cells , 2006, Immunological reviews.

[22]  Y. Belkaid,et al.  Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens , 2006, The Journal of experimental medicine.

[23]  T. van der Poll,et al.  Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. , 2006, The Journal of infectious diseases.

[24]  B. Baban,et al.  Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1 , 2005, The Journal of Immunology.

[25]  Y. Belkaid,et al.  Antigen Requirements for Efficient Priming of CD8+ T Cells by Leishmania major-Infected Dendritic Cells , 2005, Infection and Immunity.

[26]  B. Baban,et al.  A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. , 2005, International immunology.

[27]  A. Rudensky,et al.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3. , 2005, Immunity.

[28]  B. Baban,et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.

[29]  B. Baban,et al.  Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. , 2004, Journal of reproductive immunology.

[30]  D. Munn,et al.  IDO and tolerance to tumors. , 2004, Trends in molecular medicine.

[31]  B. Baban,et al.  Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion1 , 2003, The Journal of Immunology.

[32]  Y. Belkaid,et al.  CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity , 2002, Nature.

[33]  Y. Belkaid,et al.  CD8+ T Cells Are Required for Primary Immunity in C57BL/6 Mice Following Low-Dose, Intradermal Challenge with Leishmania major , 2002, The Journal of Immunology.

[34]  Y. Belkaid,et al.  A Natural Model of Leishmania major Infection Reveals a Prolonged “Silent” Phase of Parasite Amplification in the Skin Before the Onset of Lesion Formation and Immunity , 2000, The Journal of Immunology.

[35]  D. Munn,et al.  Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? , 1999, Immunology today.

[36]  Y. Belkaid,et al.  Development of a Natural Model of Cutaneous Leishmaniasis: Powerful Effects of  Vector Saliva and Saliva Preexposure on the Long-Term Outcome of Leishmania major Infection in the Mouse Ear Dermis , 1998, The Journal of experimental medicine.

[37]  R. Locksley,et al.  The regulation of immunity to Leishmania major. , 1995, Annual review of immunology.

[38]  P. Scott.  IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. , 1991, Journal of immunology.

[39]  R. Locksley,et al.  Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. , 1991, Journal of immunology.

[40]  R. Locksley,et al.  Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection. , 1991, Research in immunology.

[41]  H. Moll,et al.  Resistance to murine cutaneous leishmaniasis is mediated by TH1 cells, but disease‐promoting CD4+ cells are different from TH2 cells , 1990, European journal of immunology.

[42]  M. Lohoff,et al.  Coexistence of antigen-specific TH1 and TH2 cells in genetically susceptible BALB/c mice infected with Leishmania major. , 1989, Immunobiology.

[43]  R. Coffman,et al.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens , 1988, The Journal of experimental medicine.